Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,